Kornimate/medical-research-clean huggingface dataset:
sbrt with dibh for hcc after tace and lipiodol marking

Conditions: Hepatocellular Carcinoma

Summary: stereotactic body radiation therapy (sbrt) for hepatocellular carcinoma (hcc) with radical dose achieved similar results with radiofrequency ablation (rf) and radical surgery, according to previous studies. for tumors near great blood vessels or with a diameter more than 2cm, sbrt performs even better than rf. in current clinical practice of sbrt for small hcc, registration is achieved by planting metal markers near the tumor, which has several disadvantages: 1. the operation is invasive, increase the risk of bleeding in patients with cirrhosis; 2. the operation is of no therapeutic value; 3. metal markers can only be planted outside the tumor to avoid transplantation, which compromises the accuracy of registration via cbct. this study aims to adopt a new method of registration, transcatheter arterial chemoembolization (tace) and lipiodol marking, to analyze the recognition and clarity of lipiodol on cbct images, set-up errors and treatment efficacy. therefore to provide data to support tace and lipiodol marking over metal marker planting.


Eligibility criteria:
inclusion criteria: 1. clinically or pathologically confirmed hepatocellular carcinoma. 2. ecog 0-1. 3. bclc c 4. liver-gtv \>700ml; intrahepatic metastasis allowed but only one tumor is to be treated with sbrt and others stable for more than 3 months; distant metastasis allowed but stable for more than 6 months. 5. expected gastric/duodenum/small intestine dmax 25-35gy; colon dmax 28-38gy. prescription dose 40gy/5-10f. 6. dibh training prior to sbrt to achieve 36 seconds breath hold. 7. life expectancy \> 3 months. 8. child-pugh a5, a6 or b7. 9. liver function: alt within 1.5 times of upper limit; alt within 0.5 times of upper limit and ast within 6 times of upper limit, excluding cardiac infarction; alt within 0.5-1.5 times of upper limit and ast within 1.5 times of upper limit 10. normal ecg, without severe cardiac dysfunction 11. kidney function: cre, bun within 1.5 times of upper limit. 12. cbc: hb≥80g/l，anc≥1.0×109 /l，plt≥40×109 /l 13. without hemorrhagic tendency. 14. voluntarily participate in this trial and sign consent form. exclusion criteria: 1. participants of other clinical trials. 2. history of abdomen radiation therapy or liver transplantation. 3. history of severe cardiovascular, kidney or liver disease. 4. pregnancy or lactation. 5. suspected or confirmed of drug or alcohol abuse. 6. history of severe mental or neurological disease, compromising the ability to consent and/or ae diagnosis. 7. allergic to lipiodol.

Keywords: hepatocellular carcinoma, tace, sbrt, dibh
betaferon/ betaseron (interferon beta-1b) in patients with chronic viral cardiomyopathy

Conditions: Cardiomyopathies; Heart Diseases

Summary: chronic viral cardiomyopathy is a disease where the cardiac muscle is attacked by a virus and this may result in a reduction in the output of the heart (pump function) thereby causing complaints such as chest pain, shortness of breath and palpitations. betaferon (interferon beta-1b) is marketed for the treatment of multiple sclerosis already, but until now, it has not been proven whether it is also effective in patients with chronic viral myocardial disease. this study will be conducted to examine the efficacy and safety of betaferon in patients with this disease. the aim of the treatment is to eliminate the virus from the heart so that the heart function and clinical status can gradually improve.

the study has previously been posted by schering ag, germany. schering ag, germany has been renamed to bayer schering pharma ag, germany. bayer schering pharma ag, germany is the sponsor of the trial.

Eligibility criteria:
inclusion criteria: * unexplained heart with evidence of adeno-, entero- and/or parvoviruses which must be identified directly in the heart tissue * being in a chronic (at least 6 month after the onset of clinical symptoms) and stable phase of the disease * impaired cardiac function exclusion criteria: * severe (decompensated) or acute heart failure. * any other disease which could better explain the patient's clinical symptoms * any other severe and/or malignant disease. * suffering from convulsions, depression or suicidal ideas judged by a physician * serious viral or bacterial infections during the last weeks * pregnancy or lactation

Keywords: cardiomyopathy idiopathic chronic heart failure adenovirus enterovirus parvovirus
safety, tolerability, and immunogenicity of the adjuvanted trivalent subunit influenza vaccine and the non-adjuvanted trivalent subunit influenza vaccine compared to the non-adjuvanted trivalent split influenza vaccine in children 6 to < 72 months of age

Conditions: Influenza Disease

Summary: this study aims to evaluate the safety, tolerability, and immunogenicity of the adjuvanted trivalent subunit influenza vaccine and the non-adjuvanted trivalent subunit influenza vaccine compared to the non-adjuvanted trivalent split influenza vaccine in children 6 to \< 72 months of age.


Eligibility criteria:
inclusion criteria: 1.children 6 months to 72 months of age. exclusion criteria:children 1. who had been hospitalized at the time of enrollment 2. who had any serious reaction or hypersensitivity to any vaccine component, eggs, or chicken protein 3. who had known impairment of the immune function 4. who had fever interfering with normal daily activities at the time of enrollment 5. who had received licensed vaccines within 14 days (for inactivated vaccines) or 28 days (for live vaccines) prior to enrollment in the study 6. concomitant participation in another clinical study 7. who had surgery planned during the study period that in the investigator's opinion would have interfered with the study visits schedule.

Keywords: adjuvanted trivalent subunit influenza vaccine vaccine influenza adjuvant mf-59 pediatric
a cohort study of hydatidiform mole

Conditions: Hydatidiform Mole

Summary: the purpose of this study is to construct a cohort for the hydatidiform mole.

after being informed about the study and potential risks, all patients who meet the eligibility requirements will be enrolled.

Eligibility criteria:
inclusion criteria: 1. patients who are diagnosed with hydatidiform mole (including: complete hydatidiform mole/partial hydatidiform mole; one of twins with hydatidiform mole; ectopic pregnancy hydatidiform mole; macroscopic or microscopic hydatidiform changes indicating early complete or partial hydatidiform mole can not be excluded; atypical placental site nodule) for the first time; 2. age 13-55 years old; 3. obtain informed consent and sign an informed consent form exclusion criteria: 1. patients who are unable to cooperate with the investigation such as mental disorders or cognitive impairment 2. no histopathology diagnosis; 3. patients with other malignancies
trial comparing treatment with sinergy™ system to conservative treatment for chronic sacroiliac joint pain

Conditions: Chronic Sacroiliac Joint Pain

Summary: the purpose of this study is to evaluate the effectiveness of cooled radiofrequency denervation of the sacroiliac region using the sinergy system compared to conservative treatment in the treatment of sacroiliac joint pain.


Eligibility criteria:
inclusion criteria: * predominantly axial pain below the l5 vertebrae * \>75% pain relief from 2 separate lateral branch blocks done on different days (followed by return to baseline pain) * chronic axial pain lasting for longer than six months: 3 day average vas between 4 and 8. * age greater than 18 years. * failed to achieve adequate improvement with comprehensive non-operative treatments, including but not limited to: activity alteration, non-steroidal anti-inflammatory, physical and/or manual therapy, and fluoroscopically guided steroid injections in and around the area of pathology. * all other possible sources of low back pain have been ruled out, including but not limited to: the intervertebral discs, bone fracture, the zygapophyseal joints, the hip joint, symptomatic spondylolisthesis, tumor and other regional soft tissue structures (this is done by physical exam, medical history, and mri/ct/x-ray as required) exclusion criteria: * beck depression score \>20 or irreversible psychological barriers to recovery * spinal pathology that may impede recovery such as spina bifida occulta, spondylolisthesis at l5/s1, or scoliosis. * moderate or severe foraminal or central canal stenosis * systemic infection or localized infection at anticipated introducer entry site. * concomitant cervical or thoracic pain greater than 2/10 on a vas * uncontrolled or acute illness * chronic severe conditions such as rheumatoid/inflammatory arthritis * pregnancy * active radicular pain * immunosuppression (eg. aids, cancer, diabetes, surgery \<3 months ago) * worker's compensation, injury litigation, or disability remuneration * allergy to injectants or medications used in procedure * high narcotics use (\>30 mg hydrocodone or equivalent) * patients who smoke. termination for at least 6 months and no smoking during follow up period are acceptable with caution. * body mass index greater than 29.9 (obese). * subject unwilling to consent to the study
comparison of hydro-dissection versus ultrasonic aspirator in division of liver parenchyma in laparoscopic resection

Conditions: Liver Transection During Laparoscopic Liver Resection

Summary: background: until now, there is no agreement about the safest and feasible method for liver parenchyma transection during laparoscopic liver resection. study design: prospective, randomized, single-center the purpose of the study: comparison of short-term results of two methods of parenchyma liver transection during laparoscopic liver resection


Eligibility criteria:
inclusion criteria: * patients with benign lesions (hemangioma, focal nodular hyperplasia \[fnh\], hepatocellular adenoma, biliary cystadenoma, hydatid echinococcosis \[only with total pericystectomy\]) and malignant tumors (colorectal cancer metastases in the liver \[crlm\], hepatocellular carcinoma \[hcc\], intrahepatic cholangiocellular carcinoma, gallbladder cancer t1b-3nxmo without invasion into bile ducts and adjacent organs), which involves laparoscopic segmental or major resection of the liver. * gender: both, male and female * minimum age 18 years * maximum age: 80 years * asa physical status i-iv * bmi up to 40 kg/m2 * no simultaneous extrahepatic intra-abdominal procedures (bile duct resection, colon resection, partial duodenum resection) * total bilirubin up to 100mmol/l if jaundice presents in non-cirrhotic patients * if cirrhosis is present, class a and b according to ctp score exclusion criteria: * • difficulty index \> 12 points (see below) * tumor invasion of ivc or portal trunk (necessity of vascular reconstruction) * repeated liver resection before laparoscopic resection (the single resection before is not a contraindication) * simultaneous extra-hepatic intra-abdominal procedures (bile duct resection, colon resection etc.) * age under 18 years * age above 80 years * asa physical status \>iv * bmi \> 40 kg/m2 * total bilirubin \>100mmol/l if jaundice presents in non-cirrhotic patients * if cirrhosis is present, class c according to ctp score * persons who are incapable of giving consent * pregnant or breast-feeding women * patients enlisted in other studies

Keywords: colorectal liver metastases hepatocellular carcinoma intrahepatic cholangiocellular carcinoma tumor of liver focal nodular hyperplasia liver hemangioma liver
functional dn for shortened hs muscle

Conditions: Hamstring Contractures

Summary: the aim of this study is to find whether functional dry needle is helpful to increase the length of shortened hamstring muscle or not

single pretest-post clinical trial to find immediate effects of functional dry needling to increase the length of the shortened hamstring. this study will be carried on single group which will include male subjects only. the data will be recorded before and immediately after the treatment. a monofilament stainless steel needle will be inserted on three points on hamstring muscle which will include semitendinosus, semimembranosus and bicep femoris. treatment session will consist of 1 minute 20 seconds for each point on the hamstring and the manipulation will be performed by "pistoning technique" in which the needle will be drawn out (not fully out of skin) after inserted and then again pushed in and data will be recorded after the treatment session on the basis of increase in length of hamstring which will be measure through 90-90 slr (ake) and on the lower extremity functional scale (lefs)

Eligibility criteria:
inclusion criteria: * having hamstring length less than 80 degree during 90-90 slr on goniometer, * also the subject that suffers from knee osteoarthritis, * spondylosis, * lbp, * lumber radiculopathy, * subjects with mtrps and those with hyper lordosis were recruited in the study exclusion criteria: * subjects suffering from blood clotting disorders such as hemophilia, * those with deformities such as leg length discrepancy, * compromised immune system, * vascular diseases, * diabetes, * people with congenital or metabolic bone disease such as spondyloepiphyseal dysplasia and pregnancy were excluded from the study

Keywords: dry needling lefs 90-90 slr
postoperative pain in endodontic therapy

Conditions: Endodontic Disease; Postoperative Pain

Summary: the goal of this clinical trial is to evaluate the change in postoperative pain in mandibular premolar and first molar teeth with asymptomatic apical periodontitis when using eddy and passive ultrasonic irrigation activation methods. the null hypothesis is: "there is no difference in postoperative pain after root canal treatment between the irrigation activation systems in mandibular first molars and premolar teeth."


Eligibility criteria:
inclusion criteria: * patients aged between 18 and 55 years, medically healthy, and free from systemic diseases. * patients without pregnancy or breastfeeding status. * patients diagnosed with asymptomatic apical periodontitis confirmed through radiographic and clinical examination. * patients not having a regular intake of analgesic or anti-inflammatory drugs within the last 12 hours. * patients lacking a history of drug allergies. * teeth free from calcifications, resorptions, periodontal problems, incomplete root development, a history of endodontic treatment, traumatic occlusion, or severe coronal destruction. * teeth with a root canal curvature of 5° or less. * mandibular premolars and first molars. exclusion criteria: * teeth where the apical area could not be reached with a #8k file. * teeth with an apical diameter larger than #20k file. * patients with a periapical index (pai) score of 1 or 2. * teeth having extra canals. * teeth requiring a second local anesthesia during treatment. * teeth where a file fractured within the canal during preparation. * vital teeth. * patients reporting preoperative pain. * teeth showing clinical symptoms such as percussion or palpation sensitivity. * teeth with persistent purulent discharge.

Keywords: eddy irrigation activation passive ultrasonic irrigation
a study to evaluate renal safety of intravenous ibandronate (bondronat) in participants with metastatic bone disease due to breast cancer

Conditions: Pain; Bone Neoplasms; Neoplasm Metastasis

Summary: this study will evaluate renal function in participants with metastatic bone disease due to breast cancer receiving intravenous (iv) infusions of ibandronate (bondronat) 6 milligrams (mg), over either 15 minutes or 60 minutes, every 3 weeks. efficacy and safety of ibandronate in the 2 groups of participants will also be compared. the anticipated time on study treatment is 7 months, and the target sample size is 318 individuals.


Eligibility criteria:
inclusion criteria: * for participants of childbearing potential: negative pregnancy test and ready to use effective contraceptive measures * metastatic breast cancer with at least one bone metastasis * karnofsky index \>/= 60 * life expectancy \>/= 6 months * estimated creatinine clearance (cockcroft and gault formula) \>/= 30 milliliters per minute (ml/min) exclusion criteria: * pregnancy or breast feeding participant * participant who had a current dental problem, particularly tooth or jaw infection, trauma or surgery on tooth or jaw in the previous six weeks, medical history of jaw osteonecrosis or delayed healing after dental surgery * participant who was participating or had participated in the last 30 days to a clinical trial investigating treatments * uncontrolled brain metastasis * severe or concomitant infection * known medical history of systemic disease with renal lesion * rapidly progressing renal failure at inclusion * uncontrolled cardiac disorder * hypercalcaemia (\> 2.7 millimoles per liter \[mmol/l\]), hypocalcaemia (\< 2 mmol/l) * participant receiving nephrotoxic chemotherapy * participant eligible for haematopoietic stem cell transplantation at inclusion time * bisphosphonate therapy in the 3 weeks before randomization * known hypersensitivity to ibandronate or other bisphosphonates
clinical value of self-assessment risk of osteoporosis in chinese

Conditions: Osteoporosis

Summary: this cross-sectional study aimed to validate the effectiveness of the combined use of the osteoporosis self-assessment tool for asians (osta) and the one-minute osteoporosis risk test (iof test) in a population from wuhan, china.

this cross-sectional study was a field investigation. a total of 400 wuhan residents who visited the health examination department at our hospital were invited to participate in this study. potential participants were informed of the aim and procedures and were asked to sign an informed consent form before participation. inclusion criteria were as follows: age of at least 20 years, able to read and fill out the questionnaire, and willingness to participate. exclusion criteria were as follows: severe liver, heart, or kidney impairment, and tumor. procedures of the study were in accordance with the declaration of helsinki and were approved by the local ethics committee. the study population was divided into four groups according to age and sex: younger women (age ≤ 55 years), younger men (age ≤ 55 years), older women (age \> 55 years), and older men (age \> 55 years). a research assistant and a nurse distributed the chinese version of the iof test to participants. the chinese version of the iof test includes 10 questions, two of which are specific to women and one to men. the maximum number of risk factors is 8 for women and 9 for men. individuals were regarded as susceptible to osteoporosis risk if they answered "yes" to any of the 10 questions. to assess the grade of osteoporosis risk, the osta index was calculated by the equation (body weight (kg) - age (years))\*0.2. an osta index of -1 to -4 is regarded as medium risk, greater than -1 as low risk, and less than -4 as high risk.

Eligibility criteria:
inclusion criteria: * age of at least 20 years, able to read and fill out the questionnaire, and willingness to participate. exclusion criteria: * severe liver, heart, or kidney impairment, and tumor. procedures of the study were in accordance with the declaration of helsinki and were approved by the local ethics committee.

Keywords: osteoporosis osteoporosis self-assessment tool one-minute osteoporosis risk test asians
placebo versus sbr759 in lowering phosphate in dialysis patients

Conditions: Hyperphosphatemia; Chronic Kidney Disease

Summary: this study will compare placebo to 4 different doses of sbr759 to assess the phosphate lowering efficacy in dialysis patients.


Eligibility criteria:
inclusion criteria: 1. men or women of at least 18 years of age 2. stable maintenance of hemodialysis 3 times per week for 3 months or greater 3. controlled serum phosphate if under phosphate-binder therapy 4. patient must either be on a stable phosphate binder dose and are willing to stop their phosphate binder therapy at the beginning of the study, or not have received any phosphate binder therapy for at least 4 weeks prior to screening exclusion criteria: 1. patients who are on peritoneal dialysis 2. patients who have a transplant or parathyroidectomy scheduled during the study 3. clinically significant gi disorder 4. unstable medical condition other than chronic kidney disease 5. patient is currently being treated with oral iron 6. history of hemachromatosis, or ferritin \> 1000 ng/ml 7. transferrin saturation \> 60% 8. uncontrolled hyperparathyroidism (ipth \> 84.8 pmol/l) other protocol-defined inclusion/exclusion criteria may apply

Keywords: chronic kidney disease hemodialysis hyperphosphatemia hyperphosphatemia patients with chronic kidney disease on 3x/week hemodialysis
cranberry for prevention of urinary tract infections in multiple sclerosis patients

Conditions: Multiple Sclerosis; Urinary Tract Infections; Bladder Dysfunction

Summary: bladder dysfunction occurs at some time in most patients with multiple sclerosis and these patients are prone to have recurrent urinary tract infections. cranberry has been traditionally used for the treatment and prophylaxis of urinary tract infections but there is no reliable randomized controlled trial demonstrating evidence of cranberry's utility in this disease. the aim of our study is to assess the efficacy and safety of cranberry in the prophylaxis of urinary tract infections in patients with multiple sclerosis with a prospective randomized, double-blind and placebo-controlled clinical trial.

bladder dysfunction occurs at some time in 70 to 90% of patients with multiple sclerosis and these patients are prone to have recurrent urinary tract infections (uti), leading to an important morbidity. cranberry has been traditionally used for the treatment and prevention of uti and research suggests that its mechanism of action is preventing bacterial adherence to host cell surface membrane. however, systematic reviews show the small sample sizes and the poor quality of available trials, determining that there is no reliable evidence of effectiveness of cranberry in uti prophylaxis. therefore, to assess whether cranberry is effective in reducing uti in patients with multiple sclerosis, we have designed a randomized, double-blind, placebo-controlled trial. efficacy will be evaluated on the time to onset of a uti in the first year of treatment.

Eligibility criteria:
inclusion criteria: * adults aged 18 to 70, with multiple sclerosis, neurologically stable for at least 3 months * with an edss score ≥ 3 * symptomatic bladder dysfunction: frequency, urgency, dysuria, incontinence (at least one of these symptoms), needing intermittent catheterization or not * ambulatory at inclusion * able to undergo evaluation * informed written consent non-inclusion criteria: * regular consumption of cranberry within 3 months before inclusion * symptomatic urinary tract infection at inclusion * chronic renal failure (creatinin clearance \< 10ml/min) * patients with urinary permanent catheterization * patients with hyperuricemia and risk of uric acid lithiasis * patients with oral anticoagulant treatment (antivitamins k) * peptic ulcer * intolerance to cranberry and/or excipients * urinary tract infections antibioprophylaxis

Keywords: prophylaxis cranberry neurogenic bladder